Equity Profile

MLYS

Mineralys Therapeutics, Inc.

Health CareBiotechnology$2.1B

Aug12Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Mineralys Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious health conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market traction and demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

MLYS Q2-2026 Earnings Preview

Context

Company Snapshot

Mineralys Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious health conditions. Operating in the health care sector, it plays a crucial role in addressing unmet medical needs through its research and development efforts.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+6.74%

Avg Stock Reaction

+5.24%

Last Quarter Recap

In Q1-2026, Mineralys reported an EPS of -$0.47, beating expectations by 7.3%. The stock reacted positively, gaining 2.87% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Mineralys' upcoming earnings report, especially given its recent history of EPS surprises. However, the lack of revenue guidance adds uncertainty.

Bull Case

If the company continues its trend of beating EPS estimates, it could signal strong operational performance and boost investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or provides no guidance on revenue, it could lead to negative sentiment and a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for Q2-2026?

Given the company's history of beating EPS estimates, this figure will be critical in determining investor sentiment.

Will there be any guidance on revenue for the upcoming quarters?

Lack of revenue guidance could lead to uncertainty, while clear guidance could bolster investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Mineralys to continue its trend of EPS surprises, particularly given its recent performance.

Supporting Evidence

The company has beaten EPS estimates in 75% of its last eight quarters.

Options pricing suggests a lower expected move compared to historical averages, indicating potential for a larger reaction.

Insider selling may signal confidence in the company's future performance despite current market sentiment.

Key Risk

If the EPS comes in better than expected, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued EPS surprises against the uncertainty of revenue guidance.

Bull Confirmed If

An EPS of -$0.40 or better would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.50 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±4.58%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a modest move of about 4.58%, suggesting that investors expect some volatility around the earnings announcement.

Options are pricing ±28.1% while MLYS has averaged ±6.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

60.3%

Calls (863K)P/C Ratio: 2.39Puts (188K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.0M

38,722 sh

2 insiders

Net

$1.0M

Net selling

Most Active Insiders· 5 open-market trades

Chief Medical OfficerRodman David Malcom
$621,120.23

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Mineralys beats expectations, history suggests a potential stock increase of around 5.22%, confirming positive momentum.

In-Line / Cautious

If the results are in line but lack clear guidance, the stock may experience muted movement as investors reassess their outlook.

Miss

If the company misses expectations, history suggests a possible decline of around 5.29%, leading to increased caution among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on ongoing clinical trials and their expected timelines.
2Details on cost management strategies and their impact on future profitability.
3Insights into market demand for their products and any competitive developments.
4Management's outlook on regulatory approvals and their implications for growth.
5Any commentary on strategic partnerships or collaborations that could enhance product development.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Mineralys Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious health conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market traction and demand for its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

MLYS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+6.74%

Avg Stock Reaction

+5.24%

Last Quarter Recap

In Q1-2026, Mineralys reported an EPS of -$0.47, beating expectations by 7.3%. The stock reacted positively, gaining 2.87% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about Mineralys' upcoming earnings report, especially given its recent history of EPS surprises. However, the lack of revenue guidance adds uncertainty.

Bull Case

If the company continues its trend of beating EPS estimates, it could signal strong operational performance and boost investor confidence.

Bear Case

Conversely, if the company fails to meet expectations or provides no guidance on revenue, it could lead to negative sentiment and a decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS figure for Q2-2026?

Given the company's history of beating EPS estimates, this figure will be critical in determining investor sentiment.

Will there be any guidance on revenue for the upcoming quarters?

Lack of revenue guidance could lead to uncertainty, while clear guidance could bolster investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Mineralys to continue its trend of EPS surprises, particularly given its recent performance.

Supporting Evidence

The company has beaten EPS estimates in 75% of its last eight quarters.

Options pricing suggests a lower expected move compared to historical averages, indicating potential for a larger reaction.

Insider selling may signal confidence in the company's future performance despite current market sentiment.

Key Risk

If the EPS comes in better than expected, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued EPS surprises against the uncertainty of revenue guidance.

Bull Confirmed If

An EPS of -$0.40 or better would confirm the bull case.

Bear Confirmed If

An EPS worse than -$0.50 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±4.58%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a modest move of about 4.58%, suggesting that investors expect some volatility around the earnings announcement.

Options are pricing ±28.1% while MLYS has averaged ±6.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

60.3%

Calls (863K)P/C Ratio: 2.39Puts (188K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.0M

38,722 sh

2 insiders

Net

$1.0M

Net selling

Most Active Insiders· 5 open-market trades

Chief Medical OfficerRodman David Malcom
$621,120.23

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Mineralys beats expectations, history suggests a potential stock increase of around 5.22%, confirming positive momentum.

In-Line / Cautious

If the results are in line but lack clear guidance, the stock may experience muted movement as investors reassess their outlook.

Miss

If the company misses expectations, history suggests a possible decline of around 5.29%, leading to increased caution among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on ongoing clinical trials and their expected timelines.
2Details on cost management strategies and their impact on future profitability.
3Insights into market demand for their products and any competitive developments.
4Management's outlook on regulatory approvals and their implications for growth.
5Any commentary on strategic partnerships or collaborations that could enhance product development.